Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.
about
Antibody biomarkers in CNS demyelinating diseases - a long and winding roadMultiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatmentDiagnostic biomarkers in multiple sclerosis.Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targetsIntrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosisThe B cell response in multiple sclerosis.Therapeutics to promote CNS repair: a natural human neuron-binding IgM regulates membrane-raft dynamics and improves motility in a mouse model of multiple sclerosis.DNA-based vaccines: the future of multiple sclerosis therapy?Characterization of variations in IL23A and IL23R genes: possible roles in multiple sclerosis and other neuroinflammatory demyelinating diseasesCerebrospinal fluid in multiple sclerosis.Neurofilaments as biomarkers in multiple sclerosis.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.Clinical and neurochemical characteristics of pediatric multiple sclerosis - CSF analysis as knowledge base for differential diagnosis and pathophysiology.A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease.Oligoclonal bands in multiple sclerosis patients: worse prognosis?Oligoclonal bands in the cerebrospinal fluid and increased brain atrophy in early stages of relapsing-remitting multiple sclerosis.Body fluid biomarkers for multiple sclerosis--the long road to clinical application.Anti-CD20 monoclonal antibodies in multiple sclerosis.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys.Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis.Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.Intrathecal immunoglobulin G synthesis and brain injury by quantitative MRI in multiple sclerosis.Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual.The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis.Inflammasome Proteins As Biomarkers of Multiple Sclerosis.Should we start evaluating intrathecal IgM production clinically?Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.Biomarkers
P2860
Q28262403-6DB08022-B760-4879-99FD-0CCD47D84A4DQ28307785-AB19404B-BE14-4610-AEDC-80E5E807E7FEQ30598338-9CAE772F-C54A-4DB3-9590-C01CEA3E118DQ33565842-A57E0112-51F6-4B9E-A4AE-8446A9FB2416Q34423587-03D09C51-8DFE-4A16-A586-6D6266776B0BQ35463552-282189D5-AE5F-448C-B6AE-90268FE89DA2Q36142794-4890CCAC-CB3E-4BBD-A898-B90C3D4031EAQ36474316-5FC89270-CC71-4560-887C-8A758AAFBC53Q36542427-3A3275CC-F5A0-444B-AF24-A55A3C3B96E8Q37111883-64BF7545-4D93-4565-A8CB-2E386D4F68E7Q37538191-AA335B83-7A7E-4CF5-86BC-F6F4FAC6C2B7Q37698240-FFC6FACB-C43C-4E80-B386-A67B65319E05Q38001602-3EAA115F-84CC-4919-94E8-FAB1F17E192BQ38088747-82824C9B-923E-4A37-BD61-E767FDC2D658Q38266693-F1CD885A-BA23-4686-9563-9216B079DFDCQ38290281-478F9145-3615-4A1B-8C7F-2E5B4CC4225DQ38322452-4C1CE188-7813-49D3-A333-A66DDBCA7BD6Q38322551-AF84A001-9D0F-4FC0-AB39-26D376A37C20Q38590773-D6463D64-9F12-47B1-848C-DBAC2043DD85Q38975695-A55878B5-BE24-443E-9A82-05E803DA672DQ39027028-EF3C8792-0346-41E6-8059-84B257A063CFQ42979507-88FE98D8-DB31-4934-8C4F-F2F04169C090Q45344837-226115D0-17D8-454D-B47A-0E9B6014783AQ46028716-79F2F4E5-81A4-40AD-90CA-AB7ECD0FA4ACQ47186219-28C26269-E56D-46DF-8E34-B0707CB843E7Q48170019-FB920708-AA45-46A2-835D-FA89BF943778Q48399126-3E730EA5-0DCB-4E30-AA3A-36E1A403C7C6Q48866748-C39F72E2-F517-4873-836A-F6BE0C8E5CC4Q48932530-1E6B47F0-67C8-4C4D-9AAC-D3FC589003B6Q52332793-B734D0E4-E11D-45CB-97D4-C14C85D3AF0BQ53653405-73E16256-A4C2-4BB2-B429-D22753D042E7Q55050487-581C06C4-AC1B-4574-9F65-C28E0C6A222AQ57083573-9747E77B-1578-48AF-8FCC-02E44EA5863C
P2860
Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Intrathecal IgM synthesis pred ...... a worse disease course in MS.
@en
Intrathecal IgM synthesis pred ...... a worse disease course in MS.
@nl
type
label
Intrathecal IgM synthesis pred ...... a worse disease course in MS.
@en
Intrathecal IgM synthesis pred ...... a worse disease course in MS.
@nl
prefLabel
Intrathecal IgM synthesis pred ...... a worse disease course in MS.
@en
Intrathecal IgM synthesis pred ...... a worse disease course in MS.
@nl
P2093
P356
P1433
P1476
Intrathecal IgM synthesis pred ...... a worse disease course in MS.
@en
P2093
Alvarez-Cermeño JC
Bootello A
González-Porqué P
P304
P356
10.1212/WNL.59.4.555
P407
P577
2002-08-01T00:00:00Z